Company expands infectious disease diagnostics portfolio with first of several assays validated for dried blood spots as sample material

Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.

Measles is a highly contagious airborne disease that can lead to severe complications for infected individuals. With measles cases on the rise globally, improving and expanding access to testing for the measles virus supports broad surveillance and prevention efforts.

Diagnostics using DBS only require droplets of capillary blood to provide a reliable test result. Samples are typically taken from the fingertip and deposited onto a paper card, which can then be sent to a diagnostic laboratory for further analysis. Due to the minimally invasive sampling method and high stability of the sample, diagnostics using DBS are beneficial in routine testing, for use in studies, or in regions without developed medical infrastructure.

The possibility of using DBS instead of venous blood samples expands opportunities for practitioners as well as diagnostics laboratories investigating measles virus infections.

“Because there was no commercial assay for detecting anti-measles virus IgG antibodies using a DBS sample, diagnostic laboratories have had to validate DBS on their own. Now we can fill this gap by offering an IVDR-compliant solution,” explains Dr. Lars Komorowski, chief scientific officer of EUROIMMUN.

The Anti-Measles Virus ELISA 2.0 (IgG) can be processed manually or automatically using EUROIMMUN‘s scalable solutions available for DBS processing and ELISA.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250303312666/en/